one-sided / two-sided [General Sta­tis­tics]

posted by ElMaestro  – Denmark, 2019-03-04 09:04 (727 d 02:48 ago) – Posting: # 19997
Views: 3,181

Hi Hötzi,

» In other words, if patients are treated with the originator’s product, there is a 5% risk that it does not perform better (more efficient and/or safer) than placebo.

There is no more than a 5% risk of approving the test product (=concluding superiority) if the test product is not superior.

» If we would test for BE at the 2.5% level (95% CI) we would be overly strict and at the same time gain absolutely nothing in terms of the patient’s risk.

The patient's risk would be halved (max 2.5% chance of approving a non-BE product; CIs would get wider).

Pass or fail!

Complete thread:

 Admin contact
21,357 posts in 4,459 threads, 1,492 registered users;
online 12 (0 registered, 12 guests [including 1 identified bots]).
Forum time: Sunday 11:52 CET (Europe/Vienna)

Facts are the air of scientists.
Without them you can never fly.    Linus Pauling

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz